In 2015, rhPTH(1‐84) (Natpara; parathyroid hormone for injection) received US Food and Drug Administration (FDA) approval as an adjunct to calcium and active vitamin D to control hypocalcemia in patients with HP who are not well controlled on conventional therapy. Here, PTH is linked to Hypocalcemia.